A modern, automated platform engineered from the ground up to deliver high-quality and dramatically accelerated bioanalysis.
Location: United States
Total raised: $17.5M
Investors 1
| Date | Name | Website |
| 09.01.2025 | Swift Vent... | swift.vc |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 24.07.2025 | - | $11M | Drive Capi... |
| 25.10.2024 | Seed | $6.5M | - |
Mentions in press and media 6
| Date | Title | Description |
| 24.07.2025 | Dash Bio: $11 Million Closed To Advance Bioanalysis Platform | Dash Bio (see Pulse 2.0 profile), a bioanalysis company specializing in rapid and scalable drug development, has announced an additional $11 million in funding, bringing its total to $17.5 million. Led by The Aligned Fund, investors include... |
| 23.07.2025 | Dash Bio Raises $11M in Funding | Dash Bio, a Newton, MA-based preclinical and clinical bioanalysis company, raised $11M in funding. The round was led by The Aligned Fund, with participation from Freestyle Capital, Cybernetix Ventures, Swift Ventures, LifeX Ventures, Drive ... |
| 28.10.2024 | Dash Bio: Pioneering a New Era in Drug Development | In the world of biotechnology, time is money. Every day lost in drug development can cost lives and billions of dollars. Enter Dash Bio, a fresh face in the industry, armed with $6.5 million in seed funding. This Newton, Massachusetts-based... |
| 25.10.2024 | Dash Bio: Drug Development Company Secures $6.5 Million (Seed) | Dash Bio, an innovator in drug development services, announced that it has raised $6.5 million in seed financing. Freestyle Capital led the round, which also included Swift Ventures, LifeX Ventures, and other private investors. Even though ... |
| 24.10.2024 | Dash Bio Raises $6.5M In Seed Financing | Dash Bio, a Newton, MA-based innovator in tech-enabled services for drug development, raised $6.5M in Seed funding. The round was led by Freestyle Capital, with participation from Swift Ventures, LifeX Ventures, and other private investors.... |
| - | Dash Bio | “A modern, automated platform engineered from the ground up to deliver high-quality and dramatically accelerated clinical bioanalysis.” |